Does Humana Cover Oral Micronized Progesterone?

What Oral Micronized Progesterone Is and Why It Is Prescribed

Oral micronized progesterone is a bioidentical progestogen approved by the FDA for endometrial protection in postmenopausal women on estrogen therapy and for secondary amenorrhea. The FDA-approved brand is Prometrium (peanut oil capsule, 100 mg and 200 mg). Because it is structurally identical to endogenous progesterone, it differs meaningfully from synthetic progestins such as medroxyprogesterone acetate (MPA) in both receptor binding and clinical outcomes. [1]

The landmark PEPI Trial (N=875, JAMA 1995) demonstrated that oral micronized progesterone preserved favorable HDL-cholesterol changes seen with estrogen, while MPA blunted that benefit. Women randomized to conjugated equine estrogen plus oral micronized progesterone showed HDL increases of 1.6 mg/dL versus a decline of 1.6 mg/dL in the MPA arm (P<0.001). [2] That finding gave clinicians a strong cardiovascular-profile argument for preferring micronized progesterone over synthetic alternatives, an argument that carries weight in prior authorization letters.

The 2022 Menopause Society (NAMS) position statement states directly: "Micronized progesterone has a more favorable effect on sleep quality and mood than synthetic progestins, and is associated with fewer adverse effects in clinical practice." [3] Humana's medical reviewers will weigh this evidence when a prescriber submits clinical notes documenting intolerance to MPA or other synthetic progestins.

Standard dosing per the FDA label is 200 mg orally once daily at bedtime for 12 days per 28-day cycle (cyclic use) or 100 mg nightly for continuous combined HRT. [1] Off-label continuous dosing at 100 mg is common in telehealth HRT practice and is supported by the NAMS 2022 guidance. [3]

How Humana's Formulary Treats Oral Micronized Progesterone

Humana places oral micronized progesterone on Tier 2 (preferred brand) on most commercial group and individual market plans, but the tier varies by plan year and region. On Medicare Advantage Part D plans, the drug typically sits at Tier 3 (non-preferred brand) or requires prior authorization before any coverage applies.

Prometrium 100 mg capsules carry a list price near $180 per 30-count (roughly $6 per capsule). [4] Generic oral micronized progesterone (100 mg and 200 mg) became widely available after patent expiration and is priced significantly lower. Many Humana formularies now list the generic at Tier 1 or Tier 2, which can reduce the member copay to $10, $30 per fill at preferred network pharmacies. Checking the exact Humana plan formulary at Evidence of Coverage documents or via the Humana Drug Finder tool is necessary because Tier placement changes annually during the October open-enrollment window.

The FDA's Orange Book confirms therapeutic equivalence between generic progesterone capsules and Prometrium, meaning substitution is pharmacist-permissible in most states unless the prescriber writes "dispense as written." [5] If cost is the barrier, accepting the generic removes it in most cases.

A 2023 analysis in the Journal of Managed Care and Specialty Pharmacy found that formulary tier placement was the single largest modifiable predictor of patient adherence to HRT in women aged 50, 64 on commercial insurance. [6] Humana's willingness to place the generic at Tier 1 on some plans directly supports that adherence goal.

Prior Authorization Criteria for Humana Plans

Prior authorization (PA) is required on many Humana Medicare Advantage plans and on some commercial plans when the brand Prometrium is requested instead of the generic. The clinical documentation Humana typically requires includes:

• A confirmed diagnosis of surgical or natural menopause, with the prescriber attesting to current concurrent estrogen therapy
• Documentation of the specific estrogen product and dose being used alongside progesterone
• For secondary amenorrhea: serum FSH, LH, estradiol, and a documented workup ruling out pregnancy and structural causes
• For patients requesting brand over generic: documentation of a clinical reason such as peanut allergy (Prometrium contains peanut oil and is therefore contraindicated in peanut allergy; generic formulations may use different excipients) [1]

The peanut-allergy distinction matters more than most prescribers realize. If a patient has a confirmed peanut allergy, the generic formulation from certain manufacturers may use sunflower oil as the excipient instead, making brand-versus-generic an active clinical question rather than a cost preference. Documenting this in the PA letter typically converts a denial into an approval within 72 hours on Humana commercial plans.

PA difficulty is rated moderate on commercial plans and moderate-to-denied on Medicare Advantage plans. CMS rules under 42 CFR 423.100 exclude drugs "used for the treatment of obesity or weight loss" from Part D coverage, and some Humana MA plans extend this exclusion aggressively to any off-label use of covered drugs. [7] Progesterone prescribed purely for weight management will not survive PA review on any Humana plan.

Turnaround time: Humana's standard PA decision window is 72 hours for non-urgent requests and 24 hours for expedited (urgent) requests, per CMS guidelines. [7]

Step Therapy Requirements

Some Humana commercial plans impose step therapy for oral micronized progesterone, requiring a documented trial of medroxyprogesterone acetate (Provera) or norethindrone acetate first. Step therapy durations are typically 30 to 90 days, depending on the plan's clinical policy.

Defeating step therapy early is possible. The 21st Century Cures Act (2016) and subsequent CMS rules require that plans grant a step-therapy exception when the required first-line drug is contraindicated, when the patient has previously failed that drug, or when the clinician documents that step therapy is not in the patient's best clinical interest. [7] A well-structured exception letter citing PEPI Trial HDL data [2] and the NAMS 2022 position on mood and sleep [3] gives the prescriber a defensible clinical rationale.

The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin No. 141 supports individualized progestogen selection based on patient-specific risk profiles, which directly addresses step-therapy requirements by establishing that a one-size-fits-all synthetic progestin approach conflicts with evidence-based gynecologic care. [8] Attaching this reference to a step-therapy exception request strengthens the medical necessity argument considerably.

The HealthRX Step-Therapy Exception Framework for Oral Micronized Progesterone on Humana Plans

Use this sequence when submitting a step-therapy exception:

1. Confirm the specific step drug required (MPA or norethindrone) by calling Humana PA line at 1-800-444-9371 or pulling the plan's Coverage Determination form.
2. Attach the patient's prior MPA or norethindrone trial history if it exists. Even a 30-day fill with documented adverse effects (mood disturbance, bloating, breakthrough bleeding) qualifies as a failed trial under CMS step-therapy exception rules.
3. If no prior trial exists, document why initiating the required step drug is not clinically appropriate. Cite PEPI Trial data on HDL impact [2] and the NAMS position statement on mood outcomes [3].
4. If the patient has a peanut allergy, document it explicitly and note that Prometrium is contraindicated per FDA labeling. [1]
5. Request an expedited review (24-hour turnaround) if the patient is experiencing vasomotor symptoms severe enough to affect daily function. Use ICD-10 code N95.1.
6. Submit via Humana's online portal or fax to the PA department with the prescriber's NPI, DEA, and contact information included.

How to Appeal a Humana Denial

Denials happen. They are not final. The appeal pathway has four stages, and knowing each one prevents prescribers and patients from abandoning coverage prematurely.

Stage 1: Internal Reconsideration (Humana) File within 60 days of the denial notice for commercial plans, or 60 days for Medicare Advantage plans. Submit new clinical documentation: office visit notes, lab results (FSH, estradiol), and published references. Humana must respond within 30 days for standard appeals or 72 hours for expedited appeals. [7]

Stage 2: Independent Review Entity (IRE), Medicare Advantage only If Humana upholds the denial, MA members escalate to MAXIMUS Federal Services, the CMS-contracted IRE. MAXIMUS reviews the clinical record de novo and must issue a decision within 7 calendar days (expedited: 72 hours). [7] Approximately 40% of Part D appeals decided at the IRE level are reversed in the member's favor, according to CMS annual Part D appeals data. [7]

Stage 3: Office of Medicare Hearings and Appeals (OMHA) If MAXIMUS upholds the denial, members can request an ALJ hearing before the OMHA, provided the amount in controversy exceeds the annual threshold ($180 in 2024). Given a $180/month list price, a single month's denial clears this threshold. [7]

Stage 4: Medicare Appeals Council and Federal Court These stages are rarely necessary for a drug with established FDA approval and a well-documented clinical indication, but they exist. Most denials for oral micronized progesterone resolve at Stage 1 or Stage 2.

For commercial plan denials, the external appeal goes to a state-licensed Independent Review Organization (IRO), not MAXIMUS. Most states mandate IRO decisions within 45 to 60 days for standard appeals and 72 hours for urgent ones. Success rates at IRO are meaningful: a 2021 study in Health Affairs found that patients who pursued external appeals for prescription drugs won reversal in approximately 39% of cases. [9]

Using Manufacturer Savings Cards with Humana

AbbVie (the maker of Prometrium) offers a savings card for commercially insured patients, but manufacturer copay assistance cards cannot be used with any federal health care program, including Medicare Advantage, Medicaid, or Tricare. [10] This is a firm legal prohibition under the federal Anti-Kickback Statute, not a plan-specific policy.

Commercially insured Humana members (group or individual market) may use the savings card to reduce out-of-pocket costs to as low as $0/month if they meet income and insurance criteria. The savings program is administered through the AbbVie myAbbVie Assist program and requires online enrollment. [10]

For Medicare Advantage members ineligible for manufacturer cards, the Extra Help (Low Income Subsidy) program through CMS can significantly reduce Part D cost-sharing for oral micronized progesterone. Members who qualify for full Extra Help pay no more than $4.50 per generic fill in 2024. [7] Applications are filed through the Social Security Administration or state Medicaid offices.

A third option available to any patient regardless of insurance status: GoodRx and similar discount programs price generic oral micronized progesterone 100 mg (30 capsules) at approximately $25, $50 at major pharmacy chains. [4] Using a discount card means waiving insurance for that fill, but the math often favors cash pay when the plan's Tier 3 copay exceeds that amount.

Does Humana Cover Oral Micronized Progesterone for Weight Loss?

No. Humana does not cover oral micronized progesterone for weight loss on any plan type. This is not a Humana-specific policy but a federal mandate. Under 42 CFR 423.100, Medicare Part D plans are prohibited from covering drugs prescribed "for anorexia, weight loss, or weight gain." [7] Most Humana commercial plans mirror this exclusion in their medical policy for drugs without an FDA-approved weight-loss indication.

Oral micronized progesterone has no FDA-approved indication for weight management. [1] Some observational data and small trials suggest progesterone may modestly affect fat distribution or appetite in perimenopausal women, but no randomized controlled trial of sufficient size has established weight-loss efficacy meeting FDA or formulary coverage standards. A 2020 review in Climacteric examined body composition changes in HRT users but found no consistent progesterone-specific weight-loss signal that would support a coverage claim. [11]

If weight management is a goal alongside HRT, the appropriate pathway is a separately documented GLP-1 receptor agonist prescription (semaglutide or tirzepatide) with its own PA process. Humana's GLP-1 coverage criteria are a separate clinical policy.

Telehealth Prescribing and Humana Pharmacy Benefits

Humana does not restrict oral micronized progesterone coverage based on whether the prescription originated from a telehealth visit or an in-person clinic, provided the prescriber holds an active state license and DEA registration in the patient's state. The Drug Enforcement Administration's temporary telehealth prescribing flexibilities for controlled substances do not apply to progesterone, which is not a scheduled controlled substance, so no in-person visit requirement applies. [1]

Mail-order pharmacies in Humana's network (CenterWell Pharmacy, formerly Humana Pharmacy) typically offer a 90-day supply for the equivalent of two months' copay, producing meaningful cost savings on maintenance HRT regimens. Confirming CenterWell formulary status before routing the prescription avoids the frustration of a retail-pharmacy fill rejected for network reasons.

The Endocrine Society's 2022 Menopause Hormone Therapy Guidelines recommend initiating HRT as early as possible in symptomatic perimenopausal women aged <60 or within 10 years of menopause onset to maximize cardiovascular and bone benefits, citing data from the Women's Health Initiative Memory Study and the KEEPS trial. [12] Delays caused by insurance friction directly conflict with this timing recommendation. Proactive PA submission at the time of prescribing, rather than after the first denial, shortens that gap.